PapersFlow Research Brief
Quinazolinone synthesis and applications
Research Guide
What is Quinazolinone synthesis and applications?
Quinazolinone synthesis and applications refer to the chemical preparation of quinazolinone compounds, a class of fused heterocyclic structures, and their use in developing inhibitors of protein kinases with antitumor, antimicrobial, and anti-inflammatory activities.
The field encompasses 26,476 works focused on the chemistry, synthesis, and pharmacological properties of quinazoline compounds, including indirubin derivatives. These studies address protein kinase inhibition, antitumor activity, antimicrobial effects, and anti-inflammatory properties. Key keywords include quinazoline, synthesis, anticancer, and biological evaluation.
Topic Hierarchy
Research Sub-Topics
Quinazolinone Kinase Inhibitors
Researchers design and synthesize quinazolinone-based inhibitors targeting tyrosine kinases like EGFR and Src for cancer therapy. Structure-activity relationships and selectivity profiles are key focuses.
Quinazolinone Synthesis Methods
This sub-topic covers catalytic and green chemistry approaches for quinazolinone construction, including metal-catalyzed cyclizations and multicomponent reactions. Optimization for yield, scalability, and sustainability is emphasized.
Quinazolinone Anticancer Agents
Studies evaluate quinazolinone derivatives for antitumor activity in cell lines and xenografts, elucidating apoptosis induction and cell cycle arrest mechanisms. Clinical candidates are profiled for efficacy and toxicity.
Quinazolinone Antimicrobial Activity
Research assesses quinazolinones against bacterial and fungal pathogens, investigating membrane disruption and efflux pump inhibition. SAR studies guide development of resistance-breaking agents.
Indirubin Derivatives from Quinazolines
Investigations focus on synthetic indirubin analogs derived from quinazoline scaffolds for kinase inhibition and anti-inflammatory effects. Glycogen synthase kinase-3 targeting is a prominent theme.
Why It Matters
Quinazolinone derivatives serve as inhibitors of key enzymes in cancer pathways. For instance, "AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer" (Cross et al., 2014) describes AZD9291, a quinazoline-based irreversible EGFR tyrosine kinase inhibitor that counters T790M resistance in non-small cell lung cancer patients, providing clinical benefit after first-generation EGFR TKIs fail. Similarly, "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models" (Li et al., 2008) demonstrates BIBW2992's efficacy in lung cancer models by targeting EGFR and HER2. These applications extend to Src family kinase inhibition, as in "Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor" (Hanke et al., 1996), which shows selective inhibition supporting T cell activation studies. Such compounds impact oncology by addressing drug resistance and signaling in malignancies.
Reading Guide
Where to Start
"Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase" by Favata et al. (1998), as it introduces U0126, a highly cited quinazoline-related inhibitor of MEK and AP-1 transactivation, providing a foundational example of synthesis and kinase inhibition with 3020 citations.
Key Papers Explained
Favata et al. (1998) first identified U0126 as a MEK inhibitor in "Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase", setting the stage for kinase mapping by Fabian et al. (2005) in "A small molecule–kinase interaction map for clinical kinase inhibitors", which profiles quinazoline-like compounds across kinases. Hanke et al. (1996) built on this with Src-selective inhibition in "Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor". Cross et al. (2014) advanced EGFR applications in "AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer", while Li et al. (2008) extended to dual EGFR/HER2 inhibition in "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models".
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Focus shifts to irreversible inhibitors addressing resistance, as in Cross et al. (2014) and Li et al. (2008). No recent preprints or news coverage in the last 12 months indicates ongoing refinement of structures from high-citation works like Schindler et al. (2000) on Abl inhibition mechanisms.
Papers at a Glance
Frequently Asked Questions
What are quinazolinones?
Quinazolinones are fused heterocyclic compounds studied for their chemistry, synthesis, and pharmacological properties, including indirubin derivatives. They exhibit inhibition of protein kinases, antitumor activity, antimicrobial effects, and anti-inflammatory properties. The field includes 26,476 works with keywords like quinazoline, synthesis, and anticancer.
How do quinazolinones inhibit EGFR in lung cancer?
Quinazolinone-based irreversible TKIs like AZD9291 target the T790M mutation in EGFR, overcoming resistance to first-generation inhibitors in non-small cell lung cancer. Cross et al. (2014) showed AZD9291 provides clinical benefit in advanced EGFR-mutant NSCLC. BIBW2992 similarly inhibits EGFR/HER2 effectively in preclinical lung cancer models (Li et al., 2008).
What role do quinazolinones play in kinase inhibition?
Quinazolinones act as selective inhibitors of tyrosine kinases, such as Src family kinases and MEK. Hanke et al. (1996) identified a Src-selective inhibitor affecting T cell receptor-induced activation via Lck. Fabian et al. (2005) mapped interactions of clinical kinase inhibitors, including quinazoline derivatives, against various kinases.
What are applications of quinazolinone synthesis?
Synthesis enables production of compounds for antitumor, antimicrobial, and anti-inflammatory uses. Favata et al. (1998) identified U0126, a quinazoline-related MEK inhibitor, blocking AP-1 transactivation. These target signaling pathways in immune cells and malignancies.
What is the current state of quinazolinone research?
Research covers 26,476 papers on synthesis and biological evaluation, with high-citation works from 1992-2014 focusing on kinase inhibitors. No recent preprints or news in the last 12 months are available. Studies emphasize protein kinase inhibition and anticancer activity.
Open Research Questions
- ? How can quinazolinone structures be optimized to improve selectivity across kinase families beyond EGFR and Src?
- ? What synthesis methods enhance the potency of irreversible quinazolinone TKIs against secondary mutations like T790M?
- ? Which indirubin-derived quinazolinones best combine antitumor and anti-inflammatory effects in vivo?
- ? How do quinazolinone inhibitors interact with NFAT and calcineurin pathways in T-lymphocyte activation?
- ? What are the structural mechanisms for quinazolinone binding to Abl tyrosine kinase variants?
Recent Trends
The field maintains 26,476 works with no specified 5-year growth rate.
High-citation papers from 1992-2014 dominate, such as Favata et al. with 3020 citations on MEK inhibition.
1998No preprints or news in the last 6-12 months available, suggesting steady focus on established kinase inhibitors like AZD9291 (Cross et al., 2014, 2152 citations).
Research Quinazolinone synthesis and applications with AI
PapersFlow provides specialized AI tools for Chemistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Code & Data Discovery
Find datasets, code repositories, and computational tools
See how researchers in Chemistry use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Quinazolinone synthesis and applications with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Chemistry researchers